Literature DB >> 15653665

The promise of immuno-PET in radioimmunotherapy.

Iris Verel1, Gerard W M Visser, Guus A van Dongen.   

Abstract

Immuno-PET as a quantitative imaging procedure before or concomitant with radioimmunotherapy is an attractive option to improve confirmation of tumor targeting and especially assessment of radiation dose delivery to both tumor and normal tissues. General information about PET, PET systems, and quantification is provided in this review. The requirements for an appropriate positron emitter and characteristics of the most attractive candidate emitters for immuno-PET are discussed. An overview of preclinical and clinical immuno-PET studies reported in the literature is provided.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15653665

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


  44 in total

Review 1.  Development of radiotracers for oncology--the interface with pharmacology.

Authors:  Rohini Sharma; Eric Aboagye
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

2.  Which radionuclides will nuclear oncology need tomorrow?

Authors:  Jacques Barbet; Jean-François Chatal; François Gauché; Jacques Martino
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06       Impact factor: 9.236

3.  Surface properties and cell adhesion onto allylamine-plasma and amine-plasma coated glass coverslips.

Authors:  Marianne Crespin; Nicolas Moreau; Bernard Masereel; Olivier Feron; Bernard Gallez; Thierry Vander Borght; Carine Michiels; Stephane Lucas
Journal:  J Mater Sci Mater Med       Date:  2011-02-03       Impact factor: 3.896

Review 4.  Antibody-based imaging of HER-2: moving into the clinic.

Authors:  R E Wang; Y Zhang; L Tian; W Cai; J Cai
Journal:  Curr Mol Med       Date:  2013-12       Impact factor: 2.222

5.  ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine.

Authors:  Ferid Haddad; Ludovic Ferrer; Arnaud Guertin; Thomas Carlier; Nathalie Michel; Jacques Barbet; Jean-François Chatal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236

Review 6.  Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.

Authors:  C Andrew Boswell; Martin W Brechbiel
Journal:  Nucl Med Biol       Date:  2007-06-08       Impact factor: 2.408

7.  Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor.

Authors:  Jaspreet Singh Jaggi; Jorge A Carrasquillo; Surya V Seshan; Pat Zanzonico; Erik Henke; Andrew Nagel; Jazmin Schwartz; Brad Beattie; Barry J Kappel; Debjit Chattopadhyay; Jing Xiao; George Sgouros; Steven M Larson; David A Scheinberg
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

8.  A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies.

Authors:  Lin Li; James Bading; Paul J Yazaki; Amitkumar H Ahuja; Desiree Crow; David Colcher; Lawrence E Williams; Jeffrey Y C Wong; Andrew Raubitschek; John E Shively
Journal:  Bioconjug Chem       Date:  2007-11-08       Impact factor: 4.774

9.  ImmunoPET, [64Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model.

Authors:  Sargur Madabushi Srideshikan; Jamison Brooks; Darren Zuro; Bijender Kumar; James Sanchez; Liliana Echavarria Parra; Marvin Orellana; Paresh Vishwasrao; Indu Nair; Junie Chea; Kofi Poku; Nicole Bowles; Aaron Miller; Todd Ebner; Justin Molnar; Joseph Rosenthal; Daniel A Vallera; Jeffrey Y C Wong; Anthony S Stein; David Colcher; John E Shively; Paul J Yazaki; Susanta K Hui
Journal:  Clin Cancer Res       Date:  2019-09-23       Impact factor: 12.531

10.  (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy.

Authors:  Bernard M Tijink; Lars R Perk; Marianne Budde; Marijke Stigter-van Walsum; Gerard W M Visser; Reina W Kloet; Ludger M Dinkelborg; C René Leemans; Dario Neri; Guus A M S van Dongen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-04       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.